Table 2.
Association between clinicopathological characteristics of breast cancer patients and CDKN2B-AS1 genotypes
| Characteristics | Total | A/A | A/G | G/G | P-value |
|---|---|---|---|---|---|
| Demographics and risk factors | |||||
| Age (years) | |||||
| ≤ 45 | 98 (48.3) | 8 (44.4) | 24 (58.5) | 26 (51) | 0.38 |
| > 45 | 105 (51.7) | 10 (55.6) | 17 (41.5) | 25 (49) | |
| Smoking | |||||
| Negative | 99 (90) | 18 (100) | 37 (90.2) | 44 (86.3) | 0.248 |
| Positive | 11 (10) | 0 (0) | 4 (9.8) | 7 (13.7) | |
| Weight | |||||
| Underweight | 12 (10.9) | 4 (22.2) | 4 (9.8) | 4 (7.8) | 0.004 |
| Normal | 28 (25.5) | 7 (38.9) | 13 (31.7) | 8 (15.7) | |
| OW/Obese | 70 (63.6) | 7 (38.9) | 24 (58.5) | 39 (76.5) | |
| FH cancer | |||||
| Negative | 76 (69.1) | 13 (72.2) | 28 (68.3) | 35 (68.6) | 0.951 |
| Positive | 34 (30.9) | 5 (27.8) | 13 (31.7) | 16 (31.4) | |
| Breast problems | |||||
| Negative | 102 (92.7) | 18 (100) | 38 (92.7) | 46 (90.2) | 0.387 |
| Positive | 8 (7.3) | 0 (0) | 3 (7.3) | 5 (9.8) | |
| OCP intake | |||||
| Negative | 87 (79.1) | 17 (94.4) | 29 (70.7) | 41 (80.4) | 0.114 |
| Positive | 23 (20.9) | 1 (5.6) | 12 (29.3) | 10 (19.6) | |
| Menarche | |||||
| Late onset | 39 (35.5) | 4 (22.2) | 11 (26.8) | 24 (47.1) | 0.058 |
| Early onset | 71 (64.5) | 14 (77.8) | 30 (73.2) | 27 (52.9) | |
| Parity | |||||
| Multipara | 96 (87.3) | 14 (77.8) | 37 (90.2) | 45 (88.2) | 0.401 |
| Nullipara | 14 (12.7) | 4 (22.2) | 4 (9.8) | 6 (11.8) | |
| Gravida | |||||
| Early G1 | 105 (95.5) | 18 (100) | 38 (92.7) | 49 (96.1) | 0.443 |
| Late G1 | 5 (4.5) | 0 (0) | 3 (7.3) | 2 (3.9) | |
| Menopause | |||||
| Early | 98 (89.1) | 16 (88.9) | 37 (90.2) | 45 (88.2) | 0.953 |
| Late | 12 (10.9) | 2 (11.1) | 4 (9.8) | 6 (11.8) | |
| Breast feeding | |||||
| Negative | 92 (83.6) | 13 (72.2) | 34 (82.9) | 45 (88.2) | 0.284 |
| Positive | 18 (16.4) | 5 (27.8) | 7 (17.1) | 6 (11.8) | |
| Menopausal status | |||||
| Pre | 80 (72.7) | 14 (77.8) | 28 (68.3) | 38 (74.5) | 0.698 |
| Post | 30 (27.3) | 4 (22.2) | 13 (31.7) | 13 (25.5) | |
| Night work | |||||
| Negative | 97 (88.2) | 16 (88.9) | 36 (87.8) | 45 (88.2) | 0.993 |
| Positive | 13 (11.8) | 2 (11.1) | 5 (12.2) | 6 (11.8) | |
| Sedentary life style | |||||
| Negative | 11 (10) | 1 (5.6) | 3 (7.3) | 7 (13.7) | 0.470 |
| Positive | 99 (90) | 17 (94.4) | 38 (92.7) | 44 (86.3) | |
| Pathological data | |||||
| Side | |||||
| Right | 70 (63.6) | 11 (61.1) | 27 (65.9) | 32 (62.7) | 0.92 |
| Left | 40 (36.4) | 7 (38.9) | 14 (34.1) | 19 (37.3) | |
| Site | |||||
| Outer quadrants | 48 (43.6) | 5 (27.8) | 16 (39) | 27 (52.9) | 0.13 |
| Others | 62 (56.4) | 13 (72.2) | 25 (61) | 24 (47.1) | |
| No masses | |||||
| Single | 85 (77.3) | 12 (66.7) | 30 (73.2) | 43 (84.3) | 0.22 |
| Multiple | 25 (22.7) | 6 (33.3) | 11 (26.8) | 8 (15.7) | |
| Grade | |||||
| ≤ 2 | 90 (81.8) | 16 (88.9) | 32 (78) | 42 (82.4) | 0.60 |
| > 2 | 20 (18.2) | 2 (11.1) | 9 (22) | 9 (17.6) | |
| T stage | |||||
| ≤ 3 | 79 (71.8) | 12 (66.7) | 29 (70.7) | 38 (74.5) | 0.80 |
| > 3 | 31 (28.2) | 6 (33.3) | 12 (29.3) | 13 (25.5) | |
| N stage | |||||
| N0 | 30 (27.3) | 8 (44.4) | 10 (24.4) | 12 (23.5) | 0.20 |
| N1–3 | 80 (72.7) | 10 (55.6) | 31 (75.6) | 39 (76.5) | |
| M stage | |||||
| M0 | 50 (45.5) | 8 (44.4) | 17 (41.5) | 25 (49) | 0.76 |
| M1 | 60 (54.5) | 10 (55.6) | 24 (58.5) | 26 (51) | |
| LVI | |||||
| Negative | 58 (52.7) | 10 (55.6) | 18 (43.9) | 30 (58.8) | 0.35 |
| Positive | 52 (47.3) | 8 (44.4) | 23 (56.1) | 21 (41.2) | |
| Skin involvement | |||||
| Negative | 89 (80.9) | 14 (77.8) | 31 (75.6) | 44 (86.3) | 0.40 |
| Positive | 21 (19.1) | 4 (22.2) | 10 (24.4) | 7 (13.7) | |
| Clinical stage | |||||
| ≤ 2 | 48 (43.6) | 8 (44.4) | 17 (41.5) | 23 (45.1) | 0.93 |
| > 2 | 62 (56.4) | 10 (55.6) | 24 (58.5) | 28 (54.9) | |
| NPI | |||||
| Good | 56 (50.9) | 12 (66.7) | 19 (46.3) | 25 (49) | 0.332 |
| Poor | 54 (49.1) | 6 (33.3) | 22 (53.7) | 26 (51) | |
| Molecular subtype | |||||
| Luminal A | 52 (47.3) | 9 (50) | 16 (39) | 27 (52.9) | 0.45 |
| Luminal B | 14 (12.7) | 3 (16.7) | 3 (7.3) | 8 (15.7) | |
| HER2+ | 7 (6.4) | 1 (5.6) | 4 (9.8) | 2 (3.9) | |
| Basal | 37 (33.6) | 5 (27.8) | 18 (43.9) | 14 (27.5) | |
| IHPI | |||||
| Good | 66 (181.6) | 12 (66.7) | 19 (46.3) | 35 (68.6) | 0.25 |
| Moderate | 37 (33.6) | 5 (27.8) | 18 (43.9) | 14 (27.5) | |
| Poor | 7 (6.4) | 1 (5.6) | 4 (9.8) | 2 (3.9) | |
| Follow-up | |||||
| ESMO | |||||
| Low risk | 41 (37.3) | 9 (50) | 16 (39) | 16 (31.4) | 0.35 |
| High risk | 69 (62.7) | 9 (50) | 25 (61) | 35 (68.6) | |
| DFS | |||||
| Prolonged | 52 (47.3) | 7 (38.9) | 13 (31.7) | 32 (62.7) | 0.009 |
| Short | 58 (52.7) | 11 (61.1) | 28 (68.3) | 19 (37.3) | |
| Recurrence | |||||
| Negative | 55 (50) | 9 (50) | 19 (46.3) | 27 (52.9) | 0.82 |
| Positive | 55 (50) | 9 (50) | 22 (53.7) | 24 (47.1) | |
| OS | |||||
| Prolonged | 53 (48.2) | 2 (11.1) | 8 (19.5) | 43 (84.3) | < 0.001 |
| Short | 57 (51.8) | 16 (88.9) | 33 (80.5) | 8 (15.7) | |
Data are presented as numbers (percentage). A two-sided Chi-square test was used. Short survival was set at 12 months. Bold values indicate significance at P-value < 0.05
OW over-weight, FH family history, OCP oral contraceptive pills, G1 first pregnancy, LVI lymphovascular invasion, NPI Nottingham prognostic index, IHPI immunohistochemistry prognostic index, ESMO European Society of Medical Oncology for risk estimation of recurrence, DFS disease-free survival, OS overall survival